Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
Other Sizes |
|
Targets |
NF-kappaB[1]
|
---|---|
ln Vitro |
PTD-p65-P1 Peptide TFA (10-150 μM; 0-60 min; KBM-5 cells) suppresses TNF-induced NF-κB activation by 25% at 100 μM and totally at 150 μM[1]. It also inhibits TNF-induced NF-κB activation in a dose-dependent manner. PTD-p65-P1 Peptide TFA (150 μM; 0–60 min; KBM-5 cells) prevents nuclear translocation and cytoplasmic p65 phosphorylation[1]. TNF-induced apoptosis is potentiated from 4 to 45% in KBM-5 cells when exposed to 100 μM of PTD-p65-P1 Peptide TFA for 16 hours[1]. In A 293 cells, PTD-p65-P1 Peptide TFA (150 μM) suppresses TNF-induced NF-κB-dependent reporter gene expression[1]. SP-53 cells treated with 150 μM PTD-p65-P1 Peptide TFA for 12-24 hours suppresses cell proliferation[2].
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: KBM-5 cells Tested Concentrations: 150 μM Incubation Duration: 0, 5, 10, 15, 30 and 60 minutes Experimental Results: Suppressed TNF-induced NF-κB activation by inhibiting phosphorylation and nuclear translocation of p65. Cell Proliferation Assay[2] Cell Types: SP-53 cells Tested Concentrations: 150 μM Incubation Duration: 12 and 24 hrs (hours) Experimental Results: Inhibited cell proliferation of 40% in 12 hrs (hours) and 60% in 24 hrs (hours). |
References |
[1]. Takada Y, et, al. Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis. J Biol Chem. 20
[2]. Shishodia S, et, al. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol. 2005 Sep 1;70(5):700-13. |
Molecular Formula |
C170H276F3N57O46S
|
---|---|
Molecular Weight |
3943.52
|
Related CAS # |
PTD-p65-P1 Peptide
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O :≥ 100 mg/mL (~25.36 mM)
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.2536 mL | 1.2679 mL | 2.5358 mL | |
5 mM | 0.0507 mL | 0.2536 mL | 0.5072 mL | |
10 mM | 0.0254 mL | 0.1268 mL | 0.2536 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.